Lyell Immunopharma Inc (NASDAQ:LYEL) — Market Cap & Net Worth
Market Cap & Net Worth: Lyell Immunopharma Inc (LYEL)
Lyell Immunopharma Inc (NASDAQ:LYEL) has a market capitalization of $251.36 Million ($251.36 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15703 globally and #3715 in its home market, demonstrating a -20.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lyell Immunopharma Inc's stock price $10.78 by its total outstanding shares 23328390 (23.33 Million). Also see LYEL total assets for a full breakdown of the balance sheet.
Lyell Immunopharma Inc Market Cap History: 2021 to 2026
Lyell Immunopharma Inc's market capitalization history from 2021 to 2026. Data shows change from $180.56 Million to $251.36 Million (-8.20% CAGR). Also see LYEL operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Lyell Immunopharma Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.01% | #427 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1535 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.01% | #218 of 263 |
Weight: Lyell Immunopharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lyell Immunopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lyell Immunopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check LYEL stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
19945.77x
Lyell Immunopharma Inc's market cap is 19945.77 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $180.56 Million | $10.65 Million | -$250.22 Million | 16.95x | N/A |
| 2022 | $80.95 Million | $84.68 Million | -$183.12 Million | 0.96x | N/A |
| 2023 | $45.26 Million | $130.00K | -$234.63 Million | 348.13x | N/A |
| 2024 | $14.93 Million | $61.00K | -$342.99 Million | 244.76x | N/A |
| 2025 | $718.05 Million | $36.00K | -$274.45 Million | 19945.77x | N/A |
Competitor Companies of LYEL by Market Capitalization
Companies near Lyell Immunopharma Inc in the global market cap rankings as of September 17, 2026. Review LYEL intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Lyell Immunopharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Lyell Immunopharma Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Lyell Immunopharma Inc's market cap moved from $180.56 Million to $ 251.36 Million, with a yearly change of -8.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $251.36 Million | -64.99% |
| 2025 | $718.05 Million | +4709.38% |
| 2024 | $14.93 Million | -67.01% |
| 2023 | $45.26 Million | -44.09% |
| 2022 | $80.95 Million | -55.17% |
| 2021 | $180.56 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Lyell Immunopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $251.36 Million USD |
| MoneyControl | $251.36 Million USD |
| MarketWatch | $251.36 Million USD |
| marketcap.company | $251.36 Million USD |
| Reuters | $251.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in … Read more